#United States #New York #Diabetic Kidney Disease #Renalytix PLC #KidneyIntelX

KidneyIntelX® Delivers Revolutionary Findings on Diabetic Kidney Disease

Introduction

Renalytix PLC, a pioneering company in precision medicine diagnostics, has unveiled groundbreaking results from its extensive two-year study on diabetic kidney disease through the KidneyIntelX® system. These findings, recently published in the esteemed journal Diabetes, Obesity and Metabolism, present compelling evidence that KidneyIntelX® can not only assess patient risk but also actively alter the trajectory of kidney disease treatment and management. The research involves a significant sample size of 2,470 patients diagnosed with type 2 diabetes and early-stage chronic kidney disease (CKD) across two leading health systems in the United States.

Key Findings

The study conducted at Mount Sinai Health System in New York and Wake Forest/Atrium Health in North Carolina represents a leap forward in how kidney disease risk is quantified and treated. For the first time, a risk stratification tool has demonstrated long-term efficacy in reshaping patient outcomes over a full two-year period.

A prominent statement from Dr. David Lam, a co-principal investigator of the study, emphasizes the transformative capability of the KidneyIntelX® system. It allows clinicians to make informed, structured decisions based on biomarker-guided approaches. The implementation of this system not only helps higher-risk patients to receive more intensive treatments but also spares lower-risk patients from unnecessary escalation of therapies, fulfilling the ideals of precision medicine in practical scenarios.

Longitudinal Data

The study's longitudinal data analysis highlights the continuous evolution of outcomes linked to the KidneyIntelX® test. Here's a brief overview of the important findings:

6-Month Update: Initial results established that KidneyIntelX® influenced decision-making significantly, enhancing guideline-directed medical treatments (GDMT).
12-Month Outcomes: Further analysis revealed that risk-stratified GDMT changes correlated with substantial improvements in clinical markers such as kidney health, heart function, and metabolic conditions.
* 24-Month Findings: The most recent data indicates that KidneyIntelX® is capable of dynamically assessing risk over time, with measurable outcomes such as increased use of SGLT2 inhibitors and GLP-1 receptor agonists—a critical piece of standard therapy.

Enhanced Risk Stratification

The latest analysis shows an encouraging shift in patient classifications, with about 29% of retested patients moving to a lower risk category, highlighting the effectiveness of targeted therapies guided by KidneyIntelX® results. Significant increases in SGLT2 inhibitor utilization have been reported, reaching heights of 56% among high-risk patients, with 70% at Mount Sinai. The combination therapy of SGLT2 inhibitors and GLP-1 receptor agonists almost tripled among high-risk individuals, emphasizing a focused approach driven by real-world outcomes.

Furthermore, patients who began therapies based on KidneyIntelX® results were nearly twice as likely to achieve risk reduction, underscoring the tangible connection between clinical decision-making informed by this innovative tool and patient wellbeing. Notably, the study also showed that individuals initially categorized as high-risk were 10.4 times more susceptible to significant declines in kidney function, reinforcing the unparalleled risk separation achieved by KidneyIntelX®.

Conclusion

Dr. Joji Tokita, another co-principal investigator, remarked on the critical nature of these findings in nephrology. The study underscores that effective risk stratification can translate to real, sustainable changes in kidney health—evidenced by a 43% improvement in eGFR decline rates and notable drops in UACR and HbA1c levels among high-risk patients over the two-year period.

Overall, the KidneyIntelX® innovation emerges not just as a new diagnostic test but as a comprehensive tool that enhances clinical practices and patient outcomes in diabetic kidney disease. Renalytix, with FDA approval for ThyKidneyIntelX®, is at the forefront of revolutionizing kidney care in the United States. To learn more about the KidneyIntelX® test and its implications for patients, visit www.kidneyintelx.com.

About Renalytix PLC

Renalytix PLC is committed to improving kidney disease management through AI-driven diagnostics, aligning clinical efforts with innovative testing to facilitate patient care in the early stages of diabetic kidney disease. With the ongoing supporting infrastructure and research, Renalytix stands as a pioneer in optimizing patient outcomes in renal care.